MS-325: Albumin-targeted contrast agent for MR angiography

Radiology

Volumn 207, Issue 2, 1998, Pages 529-538

  Lauffer, Randall B ^a   Parmelee, David J ^a   Dunham, Stephen U ^a   Ouellet, Hillori S ^a   Dolan, Robert P ^a   Witte, Sonia ^a   McMurry, Thomas J ^a   Walovitch, Richard C ^a  

^a EPIX Pharmaceuticals   (United States)

Author keywords

Aorta, MR; Contrast media, experimental studies; Gadolinium; Iron; Magnetic resonance (MR), vascular studies

Indexed keywords

CONTRAST MEDIUM; GADOFOSVESET; PENTETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; FEMALE; MAGNETIC RESONANCE ANGIOGRAPHY; MONKEY; NONHUMAN; PHANTOM; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT; SIGNAL TRANSDUCTION; ULTRAFILTRATION;

EID: 0031836465     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.207.2.9577506     Document Type: Article

References (26)

1. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1997; 207:539-544.
2. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med 1991; 22:282-287.
3. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996; 3(suppl):S356-S358.
4. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for MRI. Invest Radiol 1997; 32:741-747.
5. Schmiedl U, Ogan MD, Moseley MR, Brasch RC. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: an experimental study in rats. AJR 1986; 147:1263-1270.
6. Wang SC, Wikstrom MG, White DL, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. Radiology 1990; 175:483-488.
7. Meyer D, Schaefer M, Bouillot A, Beaute S, Chambon C. Paramagnetic dextrans as magnetic resonance contrast agents. Invest Radiol 1991; 26(suppl):S50-S52.
8. Li KCP, Quisling RG, Armitage FE, Richardson D, Mladinich C. In vivo MR evaluation of Gd-DTPA conjugated to dextran in normal rabbits. Magn Reson Imaging 1992; 10:439-444.
9. Bogdanov AA, Weissleder R, Frank HW, et al. A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 1993; 187:701-706.
10. Adam G, Neuerburg J, Spuntrup E, Muhler A, Scherer K, Gunther RW. Dynamic contrast-enhanced MR imaging of the upper abdomen: enhancement properties of gadobutrol, gadolinium-DTPA-polylysine, and gadolinium-DTPA-cascade-polymer. Magn Reson Med 1994: 32:622-628.
11. Desser TS, Rubin DL, Fan Q, et al. Quantitation of saturation effects versus dose in three-dimensional time-of-flight magnetic resonance angiography with blood pool contrast agents. Invest Radiol 1994; 29(suppl):S65-S68.
12. Frank H, Weissleder R, Brady TJ. Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. AJR 1994; 162:209-213.
13. Kumar K, Sukumaran K, Chang CA, Tweedle MF, Eckelman WC. True tracer radiolabeling of gadolinium complex of 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7 triacetic acid (HP-DO3A). J Labeled Compounds Radiopharmaceuticals 1993; 33:473-482.
14. Brodersen R, Honoré B, Larsen FG. Serum albumin: a non-saturable carrier. Acta Pharm Tox 1984; 54:129-133.
15. Prince MR, Yucel EK, Kaufman JA, Harrison DC, Geller SC. Dynamic gadolinium-enhanced three-dimensional abdominal MR arteriography. JMRI 1993; 3:877-881.
16. Petersen MJ, Cambria RP, Kaufman JA, et al. Magnetic resonance angiography in the preoperative evaluation of abdominal aortic aneurysms. J Vasc Surg 1995; 21:891-898.
17. Shetty AN, Shirkhoda A, Bis KG, Alcantara A. Contrast-enhanced three-dimensional MR angiography in a single breath-hold: a novel technique. AJR 1995; 165:1290-1292.
18. Snidow JJ, Johnson MS, Harris VJ, et al. Three-dimensional gadolinium-enhanced MR angiography for aortoiliac inflow assessment plus renal artery screening in a single breath hold. Radiology 1996; 198:725-732.
19. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987; 87:901-927.
20. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. JMRI 1994; 4:301-307.
21. Rozenman Y, Zou X, Kantor HL. Signal loss by superparamagnetic iron oxide particles in NMR spin-echo images: the role of diffusion. Magn Reson Med 1990; 14:31-39.
22. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992; 358:209-215.
23. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992; 183:1-11.
24. Wilke N, Jerosch-Herold M, Stillman AE, et al. Concepts of myocardial perfusion imaging in magnetic resonance imaging. Magn Reson Q 1994; 10:249-286.
25. Dolan RP, Prasad PV, Wielopolski PA, et al. First-pass myocardial imaging with MS-325, an intravascular MRI contrast agent (abstr). In: Proceedings of the Fourth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine 1996; 686.
26. Guyton AC. Textbook of medical physiology. 6th ed. Philadelphia, Pa: Saunders, 1981; 358-382.